A Phase 3 interventional study of Lumateperone and Placebo in Major Depressive Disorder, sponsored by Intra-Cellular Therapies, Inc.. Completed at 50 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-09.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 14th largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2021, is one of 23 in phase 3, and was the 44th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 4 more countries
Ages 18–74
Janssen Research & Development, LLC · Sites in United States, Brazil, Hungary and 4 more countries
Ages 12–17
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 13 more countries
Ages 18–74
Intra-Cellular Therapies, Inc. · Sites in United States, Bulgaria, France and 4 more countries
Ages 18–65
Intra-Cellular Therapies, Inc.
Ages 18–74
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 480 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 203 across the 52 interventional studies, 136 across the 7 observational. Of the 53 that completed or were terminated, 26 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Intra-Cellular Therapies, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
2 of the studies in Depressive Disorder, Major by Johnson & Johnson that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
The study will be conducted in three periods:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the MINI and meets all of the following criteria:
Currently having an inadequate response to ADT (less than 50% improvement) as confirmed by the Investigator and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:
Exclusion Criteria:
Within the patient's lifetime, has a confirmed psychiatric diagnosis other than MDD, including:
Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lumateperone
Drug: Placebo
Lumateperone 42 mg capsules administered orally, once daily.
Matching capsules administered orally, once daily.
Montgomery-Asberg Depression Rating Scale
Change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
Time frame: Day 43
Clinical Global Impression Scale-Severity
Change from baseline to Day 43 in the Clinical Global Impression Scale-Severity (CGI-S). The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Time frame: Day 43
| Milestone | Lumateperone 42 mg | Placebo |
|---|---|---|
| Started | 242 | 238 |
| Completed | 205 | 224 |
| Not completed | 37 | 14 |
| Withdrew: Adverse event | 29 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Withdrawal by subject | 3 | 9 |
Change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
| units on a scale | Lumateperone 42 mg | Placebo |
|---|---|---|
| Montgomery-Asberg Depression Rating Scale | -14.7 ± 0.56 | -10.2 ± 0.54 |
Change from baseline to Day 43 in the Clinical Global Impression Scale-Severity (CGI-S). The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| units on a scale | Lumateperone 42 mg | Placebo |
|---|---|---|
| Clinical Global Impression Scale-Severity | -1.5 ± 0.07 | -1.0 ± 0.07 |
Collected over From signing ICF until end of study procedures (~9 weeks), including 6 weeks of double-blind treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lumateperone 42 mg | 0/242 (0%) | 2/242 (0.8%) | 138/242 (57%) |
| Placebo | 0/238 (0%) | 0/238 (0%) | 54/238 (22.7%) |
| Event | Lumateperone 42 mg | Placebo |
|---|---|---|
| Suicidal IdeationPsychiatric disorders | 1/242 | 0/238 |
| PolypectomySurgical and medical procedures | 1/242 | 0/238 |
| Event | Lumateperone 42 mg | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 54/242 | 9/238 |
| HeadacheNervous system disorders | 49/242 | 35/238 |
| SomnolenceNervous system disorders | 39/242 | 7/238 |
| Dry MouthGastrointestinal disorders | 35/242 | 11/238 |
| NauseaGastrointestinal disorders | 29/242 | 9/238 |
| DiarrhoeaGastrointestinal disorders | 13/242 | 2/238 |
| FatigueGeneral disorders | 12/242 | 1/238 |
| Age, Continuous(years) | Lumateperone 42 mg | Placebo | Total |
|---|---|---|---|
| Mean | 45.6 ± 12.79 | 46.4 ± 12.16 | 46.0 ± 12.47 |
| Sex: Female, Male(Participants) | Lumateperone 42 mg | Placebo | Total |
|---|---|---|---|
| Female | 169 | 165 | 334 |
| Male | 73 | 73 | 146 |
| Race/Ethnicity, Customized(Participants) | Lumateperone 42 mg | Placebo | Total |
|---|---|---|---|
| White | 235 | 223 | 458 |
| Black or African American | 6 | 8 | 14 |
| Asian | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Multiple | 0 | 3 | 3 |
| Region of Enrollment(participants) | Lumateperone 42 mg | Placebo | Total |
|---|---|---|---|
| Sweden | 1 | 1 | 2 |
| Argentina | 31 | 30 | 61 |
| United States | 78 | 76 | 154 |
| Poland | 83 | 78 | 161 |
| Bulgaria | 33 | 35 | 68 |
| Germany | 16 | 18 | 34 |
| Montgomery-Asberg Depression Rating Scale (MADRS)(units on a scale) | Lumateperone 42 mg | Placebo | Total |
|---|---|---|---|
| Mean | 30.8 ± 3.87 | 31.5 ± 3.98 | 31.1 ± 3.94 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Apr 2024, 30 months.
Results were first posted in Mar 2025, 11 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 30 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumateperone
Intra-Cellular Therapies, Inc. →